Epigenetic Therapy in Human Choriocarcinoma
AbstractBecause epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs) were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in choriocarcinoma cell lines. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating choriocarcinoma, with a special focus on preclinical studies. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Takai, N.; Narahara, H. Epigenetic Therapy in Human Choriocarcinoma. Cancers 2010, 2, 1683-1688.
Takai N, Narahara H. Epigenetic Therapy in Human Choriocarcinoma. Cancers. 2010; 2(3):1683-1688.Chicago/Turabian Style
Takai, Noriyuki; Narahara, Hisashi. 2010. "Epigenetic Therapy in Human Choriocarcinoma." Cancers 2, no. 3: 1683-1688.